Teachers Advisors LLC lifted its stake in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 22.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 308,538 shares of the medical research company’s stock after purchasing an additional 57,531 shares during the period. Teachers Advisors LLC owned about 0.49% of PRA Health Sciences worth $23,143,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of PRAH. Nationwide Fund Advisors grew its holdings in shares of PRA Health Sciences by 4.1% in the first quarter. Nationwide Fund Advisors now owns 44,121 shares of the medical research company’s stock worth $2,878,000 after purchasing an additional 1,723 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in PRA Health Sciences by 0.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock worth $1,428,000 after buying an additional 140 shares during the period. Bank of New York Mellon Corp lifted its holdings in PRA Health Sciences by 6.9% during the 1st quarter. Bank of New York Mellon Corp now owns 218,490 shares of the medical research company’s stock valued at $14,253,000 after buying an additional 14,059 shares in the last quarter. Swiss National Bank lifted its holdings in PRA Health Sciences by 1.9% during the 1st quarter. Swiss National Bank now owns 65,758 shares of the medical research company’s stock valued at $4,289,000 after buying an additional 1,200 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in PRA Health Sciences by 62.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 20,755 shares of the medical research company’s stock valued at $1,354,000 after buying an additional 7,999 shares in the last quarter. Hedge funds and other institutional investors own 98.37% of the company’s stock.

PRA Health Sciences, Inc. (PRAH) opened at 75.09 on Friday. The stock has a market cap of $4.70 billion, a P/E ratio of 48.48 and a beta of 0.45. PRA Health Sciences, Inc. has a 52-week low of $50.87 and a 52-week high of $80.99. The firm’s 50-day moving average is $75.71 and its 200-day moving average is $70.59.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The firm had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. During the same quarter in the prior year, the firm posted $0.63 EPS. PRA Health Sciences’s quarterly revenue was up .5% compared to the same quarter last year. Equities research analysts predict that PRA Health Sciences, Inc. will post $3.19 earnings per share for the current year.

In other PRA Health Sciences news, CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $711,075,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,000,000 shares of company stock valued at $748,500,000 over the last 90 days. 2.10% of the stock is currently owned by company insiders.

Several equities research analysts have issued reports on the stock. Jefferies Group LLC set a $73.00 price objective on shares of PRA Health Sciences and gave the company a “buy” rating in a research report on Thursday, June 1st. Credit Suisse Group restated an “outperform” rating and issued a $76.00 target price (up from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Bank of America Corporation initiated coverage on shares of PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 target price on the stock. Citigroup Inc. reaffirmed a “buy” rating and set a $90.00 target price (up from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Finally, BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $84.22.

TRADEMARK VIOLATION WARNING: “PRA Health Sciences, Inc. (PRAH) Stake Increased by Teachers Advisors LLC” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/23/pra-health-sciences-inc-prah-stake-increased-by-teachers-advisors-llc.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.